oxymatrin
one
alkaloid
extract
chines
herb
sophora
japonica
sophora
flavescen
ait
activ
antiinflamm
inhibit
immun
reaction
antiviru
protect
hepatocyt
antihepat
fibrosi
howev
effect
oxymatrin
acut
lung
injuri
ali
known
yet
studi
effect
oxymatrin
ali
investig
use
oleic
acidinduc
ali
mous
model
morpholog
find
show
oleic
acid
group
demonstr
mark
lung
injuri
repres
promin
atelectasi
intraalveolar
interstiti
patchi
hemorrhag
edema
thicken
alveolar
septum
format
hyalin
membran
exist
inflammatori
cell
alveolar
space
oxymatrinedexamethason
group
chang
less
sever
vicin
control
group
furthermor
pretreat
oxymatrin
significantli
allevi
oleic
acidinduc
lung
injuri
accompani
reduct
lung
index
wettodri
weight
ratio
decreas
serum
level
inhibit
phosphoryl
mapk
find
suggest
oxymatrin
benefici
effect
acut
lung
injuri
induc
oleic
acid
mice
may
inhibit
product
proinflammatori
cytokin
mean
inhibit
mapk
acut
lung
injuri
ali
character
intens
pulmonari
inflammatori
respons
neutrophil
accumul
interstiti
edema
disrupt
epitheli
integr
leakag
protein
alveolar
space
john
et
al
acut
respiratori
distress
syndrom
ard
character
increas
capillari
endotheli
permeabl
lead
segment
accumul
high
protein
content
interstiti
edema
fibrin
platelet
plug
occlud
microvasculatur
lung
neutrophil
sequestr
activ
interstitium
lead
segment
alveolar
damag
flood
process
result
decreas
pulmonari
complianc
compromis
ga
exchang
extens
intrapulmonari
shunt
concomit
ventilationperfus
mismatch
present
ard
often
classifi
continuum
injuri
rang
milder
form
acut
lung
injuri
ali
sever
form
ard
christoph
et
al
aliard
associ
develop
multipl
organ
dysfunct
syndrom
mod
play
import
role
death
patient
sepsi
pneumonia
aspir
gastric
content
trauma
multipl
transfus
ischemia
reperfus
sever
acut
respiratori
syndrom
sar
novel
global
infecti
diseas
induc
viru
famili
coronavirida
clinic
investig
show
patholog
chang
sar
patient
similar
acut
lung
injuri
reveal
alveolar
cell
collaps
sever
exud
acut
inflammatori
reaction
hyalin
membran
format
zhong
du
et
al
current
correct
therapi
avail
gener
accept
develop
mod
follow
gradual
rout
aliardsmod
pathway
lung
behav
central
organ
first
target
subject
injuri
pulmonari
dysfunct
may
lead
sever
hypoxemia
multipl
organ
dysfunct
failur
treatment
mention
diseas
concentr
develop
ali
take
measur
soon
possibl
research
develop
antisar
drug
also
compli
law
potenti
new
therapeut
strategi
sar
shown
includ
wide
search
drug
conduc
reduct
lung
injuri
manag
symptom
zhong
du
et
al
tradit
chines
medicin
sophora
japonica
use
treatment
mani
diseas
thousand
year
matrinelik
alkaloid
found
chief
activ
compon
chines
herb
sophora
japonica
includ
matrin
oxymatrin
sophocarpin
sophoramin
sophoridin
et
al
content
oxymatrin
composit
sophora
japonica
qi
et
al
basic
clinic
research
shown
oxymatrin
follow
pharmacolog
effect
antiinflamm
inhibit
immun
reaction
antiviru
protect
hepatocyt
antihepat
fibrosi
liu
et
al
liu
et
al
liu
chiou
chen
et
al
dong
et
al
xiang
et
al
yang
et
al
chines
bureau
scienc
technolog
announc
outbreak
sar
composit
sophora
japonica
inject
distinct
effect
treatment
sar
zhong
consid
pharmacolog
effect
oxymatrin
specul
oxymatrin
may
play
central
role
composit
inject
although
effect
oxymatrin
sar
report
date
order
test
hypothesi
pulmonari
patholog
chang
sar
similar
acut
lung
injuri
effect
oxymatrin
acut
lung
injuri
investig
use
ali
mous
model
studi
also
studi
whether
mapk
intracellular
signal
pathway
involv
develop
ali
discuss
whether
oxymatrin
could
becom
therapeut
candid
drug
ali
ard
sar
oxymatrin
obtain
yixin
pharmaceut
co
ltd
zhejiang
china
hplc
puriti
oleic
acid
purchas
linfeng
chemic
co
ltd
shanghai
china
albumin
obtain
sigma
rabbit
polyclon
antibodi
phosphoryl
nonphosphoryl
mapk
provid
cell
signal
technolog
tween
glycin
purchas
amresco
co
polyvinyliden
difluorid
pvdf
transfer
membran
western
blot
obtain
roch
molecular
biochem
quebec
canada
protein
assay
dye
reagent
purchas
jiancheng
bioengin
co
nanj
china
hrp
conjug
goat
antirabbit
igg
pipa
lysi
buffer
purchas
shengnengbocai
biotech
inc
shanghai
china
mous
elisa
assay
kit
obtain
jingmei
biotech
co
guangdong
china
reagent
highest
grade
avail
commerci
male
kunm
strain
mice
weigh
g
obtain
laboratori
anim
center
school
medicin
southeast
univers
nanj
china
mice
hous
climatecontrol
quarter
c
humid
h
lightdark
cycl
free
access
food
water
experi
conduct
accord
guid
care
use
laboratori
anim
publish
nation
institut
health
nih
public
revis
mice
randomli
assign
six
group
oleic
acid
group
receiv
mlkg
iv
oleic
acid
mix
bovin
serum
albuman
control
group
receiv
mlkg
iv
salin
three
oleic
acid
oxymatrin
group
treat
oxymatrin
three
consecut
day
oleic
acid
inject
oxymatrin
mgkg
ip
xiang
et
al
dexamethason
group
receiv
intraperiton
inject
dexamethason
dose
mgkg
h
oleic
acid
inject
oleic
acid
control
group
treat
equival
volum
salin
instead
oxymatrin
mice
sacrif
h
oleic
acid
inject
immedi
anim
sacrif
thorax
open
lung
remov
en
bloc
observ
unawar
natur
experi
left
lower
lobe
excis
fix
buffer
formalin
lung
embed
paraffin
section
stain
hematoxylin
eosin
examin
light
microscopi
evid
lung
injuri
describ
follow
alveolar
congest
hemorrhag
edema
infiltrationaggreg
neutrophil
airspac
vessel
wall
thick
alveolar
wall
hyalin
membran
format
electron
microscopi
lung
carri
sampl
fix
phosphat
buffer
ph
contain
glutaraldehyd
postfix
osmium
tetraoxid
transmiss
electron
micrograph
produc
hitachi
electron
microscop
wet
weight
whole
lung
weigh
automat
electr
balanc
lung
index
calcul
accord
follow
formula
lung
index
wet
weight
whole
lungbodi
weight
subsequ
right
lung
excis
weigh
obtain
wet
weight
lung
dri
oven
c
day
obtain
dri
weight
assess
tissu
edema
ratio
wet
weight
dri
weight
wd
ratio
calcul
left
lung
cut
piec
subject
histolog
examin
electron
microscopi
observ
blood
sampl
harvest
eye
mice
kill
blood
allow
clot
approxim
h
room
temperatur
centrifug
g
min
obtain
serum
serum
store
c
assay
quantit
accord
instruct
avail
elisa
kit
level
mice
sampl
calcul
standard
curv
gener
recombin
mice
detect
rang
assay
ngl
sampl
concentr
exceed
limit
standard
curv
repeat
dilut
three
mice
group
adopt
min
oleic
acid
inject
lung
frozen
liquid
nitrogen
measur
immedi
remov
assay
specimen
clear
fat
debri
specimen
wet
weight
mg
phenylmethylsulfonylfluorid
pmsf
mmol
ad
use
sampl
homogen
l
pipa
lysi
buffer
use
microhomogen
ice
debri
nuclei
remov
centrifug
g
c
min
supernat
obtain
use
whole
cell
lysat
protein
concentr
determin
bovin
serum
albumin
refer
standard
use
protein
assay
dye
reagent
g
protein
separ
sodium
dodecylsulfatepolyacrylamid
gel
electrophoresi
sdspage
membran
first
incub
nonfat
milk
trisbuff
salin
tb
wash
three
time
tween
tbst
membran
incub
mapk
phosphoryl
mapk
antibodi
separ
tbst
night
c
wash
three
time
tbst
incub
horseradish
peroxidaselink
goat
antirabbit
igg
h
room
temperatur
detect
tmb
substrat
horseradish
peroxidas
data
experi
express
mean
sem
statist
analyz
use
student
unpair
ttest
valu
p
consid
signific
light
microscop
find
lung
h
oleic
acid
inject
demonstr
mark
lung
injuri
resembl
seen
lung
patient
aliard
repres
promin
atelectasi
intraalveolar
interstiti
patchi
hemorrhag
edema
thicken
alveolar
septum
format
hyalin
membran
exist
inflammatori
cell
alveolar
space
fig
observ
control
group
fig
oleic
acid
oxymatrin
group
chang
less
sever
oleic
acid
group
vicin
control
group
fig
oleic
acid
dexamethason
group
chang
pronounc
close
high
dose
oxymatrinetr
group
fig
shown
fig
electron
microscop
find
lung
oleic
acid
inject
includ
epitheli
cell
swell
endoplasm
reticulum
dilat
mitochondria
swell
exist
blood
cell
inflammatori
cell
alveolar
space
fig
observ
control
group
fig
chang
improv
evid
oleic
acid
oxymatrinedexamethason
group
fig
f
valu
lung
index
wettodri
lung
weight
ratio
wd
variou
group
experiment
anim
shown
fig
oleic
acid
inject
result
increas
lung
index
wd
ratio
lung
compar
control
p
p
attenu
mgkg
p
p
mgkg
p
p
oxymatrin
treatment
contrast
mgkg
oxymatrin
diminish
two
valu
significantli
although
lower
oleic
acid
group
lowest
level
found
anim
receiv
dexamethason
treatment
play
pivot
role
mediat
oleic
acidinduc
ali
also
assess
regul
product
oxymatrin
fig
serum
level
oleic
acid
group
significantli
higher
control
group
p
treatment
oxymatrin
inhib
ite
increas
dose
depend
manner
level
highest
dose
revert
control
level
serum
level
dexamethason
group
evid
lower
oleic
acid
group
similar
control
group
suggest
increas
induc
oleic
acid
could
suppress
oxymatrin
shown
fig
level
phosphoryl
oleic
acid
group
significantli
higher
control
group
pretreat
oxymatrin
inhibit
phosphoryl
dose
depend
manner
phosphoryl
highest
oxymatrin
group
similar
control
group
contrast
total
protein
remain
unchang
xiang
colleagu
use
oxyimatrin
evalu
effect
oxymatrin
fulmin
hepat
hepatocyt
apoptosi
mous
model
oxymatrin
administ
dose
mgkg
intraperiton
id
day
xiang
et
al
initi
administ
oxymatrin
dose
mgkg
intraperiton
twice
day
three
consecut
day
result
protect
effect
could
easili
monitor
macroscop
andor
microscop
observ
use
oxymatrin
dose
mgkg
investig
relationship
dose
effect
result
show
protect
effect
observ
mgkg
mgkg
ultim
select
test
dosag
result
show
seri
patholog
chang
observ
light
electron
microscopi
intraven
administr
oleic
acid
mice
mimick
patholog
chang
clinic
aliard
satisfactorili
furthermor
lung
index
wetdri
weight
ratio
greater
ali
mice
control
group
find
agreement
report
kenji
et
al
demonstr
oleic
acidinduc
ali
mous
model
reproduc
ali
model
success
underli
mechan
ali
induc
oleic
acid
associ
cytokin
releas
stimul
monocyt
produc
core
cytokinenetwork
play
import
role
product
inflammatori
cytokin
also
migrat
adher
neutrophil
endotheli
cell
yoshimi
et
al
togeth
endotheli
cell
injuri
cytokin
result
product
superoxid
radic
subsequ
injur
alveolar
epitheli
cell
caus
ultim
pulmonari
dysfunct
present
studi
data
reveal
serum
level
higher
oleic
acid
group
control
group
oxymatrin
evid
decreas
serum
level
lung
index
well
wettodri
ratio
reduc
pulmonari
injuri
induc
oleic
acid
find
corrobor
direct
relationship
ali
also
suggest
oxymatrin
protect
effect
oleic
acidinduc
ali
fig
ultrastructur
lung
tissu
mice
without
oleic
acid
inject
repres
photomicrograph
show
epitheli
cell
swell
endoplasm
reticulum
dilat
mitochondria
swell
b
exist
red
blood
cell
c
inflammatori
cell
alveolar
space
observ
oleic
acid
group
chang
observ
control
group
improv
evid
oleic
acid
oxymatrinedexamethason
group
e
f
normal
epitheli
cell
b
swollen
epitheli
cell
c
red
blood
cell
alveolar
space
inflammatori
cell
alveolar
space
fig
effect
oxymatrin
lung
index
wettodri
weight
ratio
wd
mice
lung
injuri
induc
oleic
acid
mice
given
oxymatrin
mgkg
ip
three
consecut
day
dexamethason
mgkg
ip
h
inject
oleic
acid
control
oleic
acid
group
receiv
normal
salin
mice
sacrif
h
oleic
acid
administr
lung
index
wettodri
weight
ratio
wd
calcul
mean
sem
n
p
compar
control
p
p
compar
oleic
acid
group
fig
effect
oxymatrin
serum
level
mice
lung
injuri
induc
oleic
acid
mice
given
oxymatrin
mgkg
ip
three
consecut
day
dexamethason
mgkg
ip
h
inject
oleic
acid
control
oleic
acid
group
receiv
normal
salin
mice
sacrif
h
oleic
acid
administr
serum
level
determin
elisa
assay
mean
sem
n
p
compar
control
p
compar
oleic
acid
group
band
map
kinas
identifi
five
group
mean
densiti
level
five
group
almost
phosphoryl
map
kinas
augment
oleic
acid
group
compar
control
group
wherea
express
phosphoryl
map
kinas
markedli
attenu
oxymatrin
group
compar
oleic
acid
group
report
oxymatrin
concentr
higher
lung
heart
organ
signifi
antiali
effect
oxymatrin
pharmcokinet
basi
wang
wang
addit
dexamethason
posit
control
exert
signific
prevent
effect
oleic
acidinduc
ali
injuri
might
explain
potent
antiinflamm
effect
describ
follow
diminut
alveolocapillari
permeabl
reduct
alveolar
epitheli
respons
pathogen
stabil
cell
lysosom
membran
enhanc
surfact
releas
prevent
microthrombogenesi
blockad
neutrophil
activ
wang
et
al
su
et
al
stimuli
differ
aliard
pathogen
wide
complic
signal
transduct
process
occur
mani
differ
cell
although
detail
mechan
still
unknown
mitogenactiv
protein
kinas
mapk
paid
special
attent
mapk
cytokinesuppress
antiinflammatori
drug
target
first
discov
lee
et
al
report
demonstr
mapk
respons
regul
inflammatori
respons
nick
et
al
nick
et
al
fang
et
al
hand
arcaroli
et
al
report
central
role
develop
ali
either
hemorrhag
endotoxemia
thu
role
mapk
develop
ali
still
uncertain
result
mapk
propos
valid
target
clinic
manag
aliard
order
examin
role
mapk
ali
analyz
express
mapk
evalu
effect
oxymatrin
express
map
kinas
shown
use
western
blot
analysi
result
show
phosphoryl
map
kinas
augment
oleic
acid
group
compar
control
group
wherea
express
phosphoryl
map
kinas
attenu
oxymatrin
group
compar
oleic
acid
group
concentrationdepend
manner
suggest
administr
oxymatrin
ali
markedli
attenu
activ
map
kinas
lung
injuri
report
augment
via
activ
map
kinaserel
intracellular
signal
pathway
johnson
et
al
lee
et
al
oxymatrin
markedli
attenu
phosphoryl
map
kinas
disturb
mechan
product
thu
result
lower
serum
level
find
conclud
oxymatrin
amelior
ali
attenu
product
proinflammatori
cytokin
attenu
associ
suppress
map
kinas
activ
addit
result
confirm
map
kinas
play
import
role
develop
oleic
acidinduc
ali
base
result
previou
report
expect
map
kinas
may
becom
promis
target
clinic
manag
ali
although
need
support
anim
experi
clinic
data
report
shown
least
three
type
map
kinas
extracellular
signalregul
protein
kinas
cjun
ntermin
protein
kinas
jnk
map
kinas
davi
kyriaki
et
al
bogoyevitch
et
al
han
et
al
raingeaud
et
al
xia
et
al
nfb
pathway
also
report
involv
process
ali
togeth
three
type
mapk
nfb
may
creat
network
regul
inflammatori
respons
ali
studi
studi
effect
oxymatrin
mapk
studi
need
elucid
whether
oxymatrin
modul
effect
pathway
china
pure
oxymatrin
inject
avail
hospit
treatment
hepat
tumor
mani
year
howev
use
aliardssar
clinic
sinc
result
indic
oxymatrin
prevent
mice
oleic
acidinduc
ali
hope
oxymatrin
use
treat
aliardssar
although
research
carri
anim
experi
clinic
trial
paper
found
oxymatrin
benefici
effect
ali
mice
first
time
although
detail
mechan
oxymatrin
remain
unravel
present
result
suggest
oxymatrin
improv
acut
lung
injuri
attenu
product
attenu
associ
suppress
map
kinas
activ
